🇺🇸 FDA
Patent

US 11925626

Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

granted A61KA61K31/437A61K47/10

Quick answer

US patent 11925626 (Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound) held by Corcept Therapeutics Incorporated expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/437, A61K47/10, A61K47/14, A61K47/22